A pill for cancer prevention?

Scientists at the University of Oklahoma, working under the guidance of Dr. Doris Benbrook, identified the compound SHetA2, which prevents cell malignancy and suppresses tumor growth and the formation of tumor blood vessels.

SHetA2 belongs to the group of Flex-Het (flexible heteroarotinoids, plastic heteroarotinoids) – compounds capable of affecting certain cellular structures and suppressing malignant cell growth. Specialists are testing the effectiveness of Flex-Het group drugs for the treatment of various diseases, including polycystic kidney disease, kidney cancer and ovarian cancer.

In preclinical studies, the authors have successfully confirmed the antitumor effect of SHetA2 for 12 types of human cancer. They have patented the results of their work (Treatment and inhibition of disease conditions using flexible heteroarotinoids, US Patent 20060252817) and hope to begin clinical trials of the compound within the next five years, and eventually develop a preventive antitumor dietary supplement based on it.

SHetA2 can theoretically be used to prevent cancer recurrence after courses of traditional radio and chemotherapy, especially in the treatment of diseases diagnosed at late stages. In addition, the patent states that various modifications of the Flex-Het group compounds can also be used to treat other diseases or conditions associated with abnormal cell differentiation, diabetes mellitus, hemophilia, liver diseases and much more, including obesity and elevated cholesterol levels.

Have we really waited for the discovery of a panacea?

Portal "Eternal youth" www.vechnayamolodost.ru based on the materials of ScienceDaily

16.05.2008